Business Context and Reporting Period
This Form 10-Q is filed by Brooks Automation, Inc. (the source filing does not identify the registrant as Azenta, Inc.). It covers the fiscal quarter and six months ended March 31, 2021, compared with the corresponding periods ended March 31, 2020. The company operated through Brooks Semiconductor Solutions Group, Brooks Life Sciences Products, and Brooks Life Sciences Services.
The financial statements are unaudited and presented under U.S. GAAP. The semiconductor cryogenics business sold in July 2019 is reported as discontinued operations.
Key Financial Metrics
| Metric | Three months ended March 31, 2021 | Prior year | Six months ended March 31, 2021 | Prior year |
|---|---|---|---|---|
| Revenue | $286.6 million | $220.2 million | $536.1 million | $430.7 million |
| Gross profit | $127.3 million | $90.3 million | $240.4 million | $175.3 million |
| Gross margin | 44.4% | 41.0% | 44.8% | 40.7% |
| Operating income | $30.5 million | $14.6 million | $61.4 million | $25.2 million |
| Income from continuing operations | $23.9 million | $9.2 million | $50.9 million | $22.4 million |
| Net income | $23.7 million | $9.1 million | $49.8 million | $22.2 million |
| Diluted EPS | $0.32 | $0.12 | $0.67 | $0.30 |
Approximate net margin was 8.3% for the quarter and 9.3% for the six-month period. Six-month operating cash flow was $77.9 million, compared with cash used in operating activities of $40.1 million in the prior-year period, which included $91.5 million of cash taxes related to the divestiture.
- Cash and cash equivalents were $320.1 million at March 31, 2021; cash, restricted cash, and marketable securities totaled $334.3 million.
- Total debt was $50.1 million of principal, or $50.1 million net of approximately $0.3 million of deferred financing costs. The company had no revolver borrowings and approximately $54.2 million of available revolving capacity.
- Capital expenditures were $25.5 million, acquisition spending was $15.1 million, and dividends paid were $14.9 million during the first six months.
- Accounts receivable increased to $225.4 million from $188.3 million at September 30, 2020; inventories increased to $128.0 million from $114.8 million.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased 30%, while six-month revenue increased 24%. Quarterly and six-month operating income increased 109% and 143%, respectively.
- Semiconductor Solutions revenue increased 26% for the quarter and 18% for the six months, led by automation products, partly offset by lower contamination-control revenue.
- Life Sciences Products revenue increased 69% for the quarter and 61% for the six months, primarily due to higher consumables and instruments demand.
- Life Sciences Services revenue increased 20% for the quarter and 19% for the six months, led by GENEWIZ sequencing and gene-synthesis services. The Trans-Hit Biomarkers acquisition contributed to results beginning in December 2020.
- Operating expenses increased to $96.8 million for the quarter and $179.0 million for the six months, driven principally by higher selling, general and administrative costs, stock-based compensation, acquisition-related costs, and separation-related costs.
- The company accrued $6.1 million for a GENEWIZ tariff matter, including $5.5 million related to prior periods. Management stated that basic and diluted EPS were reduced by $0.07 for both the quarter and six months.
- COVID-19-related demand increased Life Sciences revenue by an estimated $17 million in the quarter and $28 million in the six months, and increased Life Sciences operating income by approximately $9 million and $15 million, respectively.
- The company acquired Trans-Hit Biomarkers for approximately $15.2 million and recorded approximately $11.6 million of goodwill and purchase-accounting adjustments during the six months.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide specific quantitative revenue or earnings guidance. Management stated that it expects adequate resources to fund working capital, debt service, capital expenditures, and operations for at least the next twelve months. Semiconductor demand remains cyclical, and longer-term liquidity needs are difficult to predict.
- COVID-19 has not had a substantial negative impact to date, but future effects could include lower customer demand, supply-chain constraints, employee disruptions, or changes in virus-related research demand.
- The company had $266.4 million of non-cancellable commitments, including $230.1 million for inventory purchases, $19.8 million for information technology, and $15.8 million for China facility commitments.
- The company expects an additional $43 million to $47 million of capital expenditures over four years for its Suzhou, China facility.
- Edwards asserted indemnification claims related to the 2019 divestiture. The company could not determine the probability or amount of any potential loss, but did not believe the claims would materially affect its financial position or results.
- As of March 31, 2021, letters of credit totaled approximately $1.3 million; none had been called and management did not expect near-term calls.
- Variable-rate debt creates interest-rate exposure; a hypothetical 100-basis-point change would have changed six-month interest expense by approximately $0.3 million.
- Subsequent events included the April 2021 acquisition of Precise Automation for approximately $70 million and the May 2021 announcement of a planned spin-off of the Semiconductor Solutions Group, targeted for completion before the end of calendar 2021, subject to conditions and board approval.
- The board declared a $0.10-per-share dividend payable June 25, 2021. Future dividends remain discretionary and could be reduced, delayed, or canceled.
Most Important Facts for Investors to Verify
- Confirm the registrant identity and corporate name because the provided filing is for Brooks Automation, Inc., despite the request metadata identifying Azenta, Inc.
- Assess the sustainability of revenue and margin gains after the estimated COVID-19 benefit and after excluding the one-time tariff accrual.
- Review the financial, tax, and operational implications of the proposed Semiconductor Solutions Group spin-off.
- Monitor execution of the Precise Automation acquisition, the Suzhou facility build-out, and the company’s substantial purchase commitments.
- Evaluate exposure to semiconductor cyclicality, supply-chain disruption, foreign exchange, variable-rate debt, and potential Edwards indemnification claims.
- Reconcile reported operating performance with higher acquisition, stock-based compensation, separation, amortization, and other unallocated corporate costs.